AzarGen Biotechnologies Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

AzarGen Biotechnologies General Information

Description

Developer of human therapeutic proteins designed to increase the survivability of premature-born infants. The company's therapeutic proteins are made using advanced plant-based genetic engineering and synthetic biology techniques and it also offers a plant-based expression technology that comprises optimal combinations of novel synthetic promoters, combined with enhancer and purification components, enabling medical professionals to provide drugs with superior clinical efficacy at low cost to improve the health status of citizens and address unmet medical needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Launchlab Hammanshand Road
  • Stellenbosch, Western Cape 7600
  • South Africa
+27 021
Primary Industry
Biotechnology
Corporate Office
  • Launchlab Hammanshand Road
  • Stellenbosch, Western Cape 7600
  • South Africa
+27 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AzarGen Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-May-2024 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 27-Jun-2016 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series B) 07-Jan-2016 $3.1M $3.1M Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view AzarGen Biotechnologies’s complete valuation and funding history, request access »

AzarGen Biotechnologies Patents

AzarGen Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015262984-A1 Synthetic promoter construct for transgene expression Inactive 19-May-2014
EP-3146053-A1 Synthetic promoter construct for transgene expression Inactive 19-May-2014
US-20150329869-A1 Synthetic promoter construct for transgene expression Active 19-May-2014
US-9670497-B2 Synthetic promoter construct for transgene expression Active 19-May-2014
WO-2015177659-A1 Synthetic promoter construct for transgene expression Inactive 19-May-2014 C12N15/8216
To view AzarGen Biotechnologies’s complete patent history, request access »

AzarGen Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AzarGen Biotechnologies FAQs

  • When was AzarGen Biotechnologies founded?

    AzarGen Biotechnologies was founded in 2003.

  • Where is AzarGen Biotechnologies headquartered?

    AzarGen Biotechnologies is headquartered in Stellenbosch, South Africa.

  • What is the size of AzarGen Biotechnologies?

    AzarGen Biotechnologies has 4 total employees.

  • What industry is AzarGen Biotechnologies in?

    AzarGen Biotechnologies’s primary industry is Biotechnology.

  • Is AzarGen Biotechnologies a private or public company?

    AzarGen Biotechnologies is a Private company.

  • What is AzarGen Biotechnologies’s current revenue?

    The current revenue for AzarGen Biotechnologies is .

  • How much funding has AzarGen Biotechnologies raised over time?

    AzarGen Biotechnologies has raised $3.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process